Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

24.00 +0.44 (+1.85%)
Streaming Delayed Price Updated: 12:59 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 782,663
Open 23.60
Bid (Size) 23.94 (100)
Ask (Size) 24.05 (400)
Prev. Close 23.56
Today's Range 23.03 - 24.05
52wk Range 9.600 - 30.58
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally ↗
Centessa Pharmaceuticals develops therapies for rare and serious diseases, advancing a pipeline of clinical-stage and emerging candidates. 
Via The Motley Fool
Topics ETFs

Performance

YTD
+1.3%
+1.3%
1 Month
+9.0%
+9.0%
3 Month
-10.1%
-10.1%
6 Month
+40.0%
+40.0%
1 Year
+39.0%
+39.0%

More News

Read More
News headline image
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
Via The Motley Fool
News headline image
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
Via The Motley Fool
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
Via The Motley Fool
News headline image
Why Centessa Pharmaceuticals Stock Crushed the Market Today ↗
Via The Motley Fool
News headline image
Neural Gold Rush: Is Brain Data the Most Precious Commodity of the Century?
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
Via Chartmill
News headline image
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
This Domino's Pizza Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
CENTESSA PHARMACEUTICALS-ADR (NASDAQ:CNTA) Shows Strong Technical Setup for Potential Breakout ↗
Via Chartmill
News headline image
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗
Via Benzinga
News headline image
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire

Frequently Asked Questions

Is Centessa Pharmaceuticals plc - American Depositary Shares publicly traded?
Yes, Centessa Pharmaceuticals plc - American Depositary Shares is publicly traded.
What exchange does Centessa Pharmaceuticals plc - American Depositary Shares trade on?
Centessa Pharmaceuticals plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Centessa Pharmaceuticals plc - American Depositary Shares?
The ticker symbol for Centessa Pharmaceuticals plc - American Depositary Shares is CNTA on the Nasdaq Stock Market
What is the current price of Centessa Pharmaceuticals plc - American Depositary Shares?
The current price of Centessa Pharmaceuticals plc - American Depositary Shares is 24.00
When was Centessa Pharmaceuticals plc - American Depositary Shares last traded?
The last trade of Centessa Pharmaceuticals plc - American Depositary Shares was at 02/12/26 12:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.